Abstract 2333: Modulation of Bax and mTOR for cancer therapeutics
Rui Li(Wuhan University), Xingming Deng(Emory University), Guojing Zhang(Emory University), Shi‐Yong Sun(Emory University), Jia Zhou(Io Therapeutics (United States)), Gabriel Sica(Emory University), Walter J. Curran(Piedmont Cancer Institute), Andrew T. Magis(Institute for Systems Biology), Melissa Gilbert‐Ross(Emory Healthcare), Dongkyoo Park(Central South University), Fadlo R. Khuri(American University of Beirut Medical Center), Adam I. Marcus(Emory Healthcare), Wei Zhou(Emory University), Chunyong Ding(Shanghai Jiao Tong University), Haian Fu(Emory University), Zhuo Chen(Fujian Institute of Research on the Structure of Matter), Jun Zhang(Tencent (China)), Guo Chen(Jinan University), Maohua Xie(Central South University), Ye Ding(Tianjin University), Dong M. Shin(Emory University), Suresh Ramalingam(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center)
Cited by 0
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k